1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

FUJIFILM Diosynth Biotechnologies to Manufacture TG Therapeutics' MS Drug

05 Nov 2024
Admin
News Article

FUJIFILM Diosynth Biotechnologies to Manufacture TG Therapeutics' MS Drug

Overview

FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing organization (CDMO), has announced a multi-year manufacturing supply agreement with TG Therapeutics Inc. for BRIUMVI, a therapy for relapsing forms of multiple sclerosis (RMS).

Terms of the Agreement

Under the terms of the agreement, FUJIFILM Diosynth Biotechnologies will provide secondary manufacturing supply for BRIUMVI at its new biopharmaceutical manufacturing facility in Holly Springs, North Carolina.
The facility is expected to be fully operational in 2025.

From the CEO of FUJIFILM Diosynth Biotechnologies

“This commitment recognizes the expertise, capacity and capabilities that FUJIFILM Diosynth Biotechnologies provides with our fully integrated manufacturing network,” said Lars Petersen, president and CEO, FUJIFILM Diosynth Biotechnologies.
“FUJIFILM Diosynth Biotechnologies is executing an aggressive expansion strategy, providing customers access to our manufacturing network across the United States, Europe, and Japan for the purpose of meeting the growing demand for biotherapeutics and ultimately making patients’ lives better.”

Words from the CEO: TG Therapeutics

Michael S. Weiss, chairman and CEO of TG Therapeutics stated, “We are excited to partner with FUJIFILM Diosynth Biotechnologies as a secondary manufacturer of BRIUMVI here in the United States, and believe their expertise makes them an ideal partner for us. As we expand our commercialization efforts in MS and think about the future for BRIUMVI, we believe this is an important next step that will continue to support our growth plans and provide additional security for the supply of BRIUMVI.”